← Latest news 
Indian pharma Q4 outlook mixed as Revlimid drag hits generics and hospitals stay steady
Economy
Published on 4 May 2026
A key drug loss is reshaping generic earnings
Indian pharma and healthcare companies are entering a mixed March quarter. Hospital networks expect steady growth, supported by demand across segments. But generic drugmakers are wrestling with lost Revlimid sales and pricing pressures that weigh on performance. Analysts see pockets of strength: Lupin and Divi’s look set to do well, while Sun Pharma and Torrent show resilience. Apollo Hospitals projects strong overall traction.
- Hospitals expect steadier growth in the March quarter
- Generics face Revlimid sales loss and pricing pressure
- Lupin and Divi’s are positioned for stronger performance
- Sun Pharma, Torrent and Apollo show resilience and traction
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times